Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytori Therapeutics Inc    CYTX

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 12,2 M
EBIT 2017 -24,8 M
Net income 2017 -26,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 22,6 M
EBIT 2018 -12,6 M
Net income 2018 -13,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 2,63x
Capi. / Sales2018 1,42x
Capitalization 32,1 M
More Financials
Company
Cytori Therapeutics, Inc. is a late stage cell therapy company. that engages in the developement of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions.Data from preclinical studies and clinical trials suggest that Cytori Cell... 
More about the company
Surperformance© ratings of Cytori Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on CYTORI THERAPEUTICS INC
04/27 Cytori to Webcast First Quarter Financial Results on May 11
04/12 CYTORI THERAPEUTICS, INC. (NASDAQ : CYTX) Files An 8-K Entry into a Material Def..
04/12 CYTORI THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Unregist..
04/11 Cytori Announces Pricing of $9.5M Public Offering of Common Stock
04/11 CYTORI THERAPEUTICS INC : Today's Research Reports on Biotech Stocks to Watch: C..
04/11 CYTORI THERAPEUTICS : Receives U.S. FDA Approval for Burn Clinical Trial Related..
04/10 Cytori Announces Proposed Public Offering of Common Stock
04/10 NETWORKNEWSBREAKS – CYTORI (NA : CYTX) Shares Surge on FDA Approval for RE..
04/10 CYTORI THERAPEUTICS, INC. (NASDAQ : CYTX) Files An 8-K Other Events
04/10 CYTORI THERAPEUTICS, INC. : Other Events (form 8-K)
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
04/24DJWHAT'S NEWS : Business & Finance -- WSJ
04/24 Becton Dickinson to acquire Bard for $24 billion
04/23DJBECTON DICKINSON AND : to Acquire C.R. Bard for $24 Billion
04/19DJCardinal Swoops In, Strikes Deal -- WSJ
04/18DJCARDINAL HEALTH : $6.1 Billion Deal for Some Medtronic Operations Raises Debt Co..
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
2016 Cytori Therapeutics' (CYTX) CEO Marc Hedrick on Q1 2016 Results - Earnings Ca..
2016 Cytori Therapeutics EPS in-line, beats on revenue
2016 Cytori Cell Therapy an Orphan Drug in Europe for scleroderma-related hand dys..
2016 Notable earnings after Tuesday?s close
2016 Cytori's late-stage study of ECCS-50 in scleroderma 50% enrolled; study to co..
Advertisement
Chart CYTORI THERAPEUTICS INC
Duration : Period :
Cytori Therapeutics Inc Technical Analysis Chart | CYTX | US23283K1051 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 6,92 $
Spread / Average Target 553%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Marc H. Hedrick President, Chief Executive Officer & Director
David M. Rickey Chairman
Tiago Girão CFO, Vice President & Head-Investor Relations
John K. Fraser Chief Scientist
Mark T. Marino Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CYTORI THERAPEUTICS IN..-4.14%32
MEDTRONIC PLC16.71%112 440
BAXTER INTERNATIONAL I..24.99%30 127
ZIMMER BIOMET HOLDINGS..14.44%25 217
C R BARD INC36.02%21 962
HOYA CORPORATION8.88%18 718
More Results